Uniunea Europeană -
daneză -
EMA (European Medicines Agency)
calquence
astrazeneca ab - acalabrutinib - leukæmi, lymfocytisk, kronisk, b-celle - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.
Uniunea Europeană -
daneză -
EMA (European Medicines Agency)
imbruvica
janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.
Danemarca -
daneză -
Lægemiddelstyrelsen (Danish Medicines Agency)
bendamedac 2,5 mg/ml pulver til koncentrat til infusionsvæske, opløsning
medac, gesellschaft für klinische spezialpräparate mbh - bendamustinhydrochloridmonohydrat - pulver til koncentrat til infusionsvæske, opløsning - 2,5 mg/ml
Danemarca -
daneză -
Lægemiddelstyrelsen (Danish Medicines Agency)
bendamustin "actavis" 2,5 mg/ml pulver til koncentrat til infusionsvæske, opløsning
actavis group ptc ehf. - bendamustinhydrochlorid - pulver til koncentrat til infusionsvæske, opløsning - 2,5 mg/ml
Danemarca -
daneză -
Lægemiddelstyrelsen (Danish Medicines Agency)
bendamustine "fresenius kabi" 2,5 mg/ml pulver til koncentrat til infusionsvæske, opløsning
fresenius kabi ab - bendamustinhydrochlorid - pulver til koncentrat til infusionsvæske, opløsning - 2,5 mg/ml
Danemarca -
daneză -
Lægemiddelstyrelsen (Danish Medicines Agency)
bendamustinhydrochlorid "accord" 2,5 mg/ml pulver til koncentrat til infusionsvæske, opløsning
accord healthcare b.v. - bendamustinhydrochlorid - pulver til koncentrat til infusionsvæske, opløsning - 2,5 mg/ml
Danemarca -
daneză -
Lægemiddelstyrelsen (Danish Medicines Agency)
bendamustinhydrochlorid "medac" 2,5 mg/ml pulver til koncentrat til infusionsvæske, opløsning
medac, gesellschaft für klinische spezialpräparate mbh - bendamustinhydrochloridmonohydrat - pulver til koncentrat til infusionsvæske, opløsning - 2,5 mg/ml
Danemarca -
daneză -
Lægemiddelstyrelsen (Danish Medicines Agency)
bendamustinhydrochlorid "stada" 2,5 mg/ml pulver til koncentrat til infusionsvæske, opløsning
stada arzneimittel ag - bendamustinhydrochloridmonohydrat - pulver til koncentrat til infusionsvæske, opløsning - 2,5 mg/ml
Danemarca -
daneză -
Lægemiddelstyrelsen (Danish Medicines Agency)
bendamustinhydrochlorid "stada arzneimittel ag" 2,5 mg/ml pulver til koncentrat til infusionsvæske, opløsning
stada arzneimittel ag - bendamustinhydrochloridmonohydrat - pulver til koncentrat til infusionsvæske, opløsning - 2,5 mg/ml
Danemarca -
daneză -
Lægemiddelstyrelsen (Danish Medicines Agency)
bendamyl 2,5 mg/ml pulver til koncentrat til infusionsvæske, opløsning
viatris limited - bendamustinhydrochlorid - pulver til koncentrat til infusionsvæske, opløsning - 2,5 mg/ml